New Treatment Options for Colorectal Cancer
- 22 July 2004
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (4) , 391-392
- https://doi.org/10.1056/nejme048151
Abstract
Epidermal growth factor receptor (EGFR) is a member of the HER family of tyrosine kinase cell-surface receptors that are dysregulated in many types of tumor; its expression has been associated with a poor prognosis in colon cancer.1 There are at least two opportunities to interfere with EGFR signaling that are being exploited clinically.2 In one approach, the extracellular receptor domain is bound by antibodies, such as cetuximab, that block ligand-mediated dimerization and subsequent activation of the receptor. In the second, the tyrosine kinase domain is bound by drugs that inhibit phosphorylation, such as gefitinib and erlotinib.Irinotecan is a topoisomerase . . .Keywords
This publication has 11 references indexed in Scilit:
- The Price Tag on Progress — Chemotherapy for Colorectal CancerNew England Journal of Medicine, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigationCancer Treatment Reviews, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer TreatmentJNCI Journal of the National Cancer Institute, 2003
- Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III TrialJournal of Clinical Oncology, 2003
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialPublished by Elsevier ,2000